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Introduction
Current stagnation in survival improvements 
in treatments of advanced oesophagogastric 
cancers
Gastric cancer is the fifth most common cancer, 
and the third leading cause of cancer-related 
deaths worldwide.1 Oesophageal cancer is less 
common, however it accounts for a dispropor-
tionate amount of the total cancer deaths each 
year internationally.1 Most cases of both cancers 
are diagnosed at a late stage, when treatment 
options are usually restricted to palliative chemo-
therapy. Although serial incremental survival 
benefits particularly in gastric cancer have been 
observed,2 for most populations with advanced 
disease median overall survival (mOS) has pla-
teaued. This is despite the enhanced efficacy 
added by targeted therapies, including trastu-
zumab in human epidermal growth factor recep-
tor 2 (HER2)-positive disease in the first-line3 
and anti-vascular endothelial growth factor recep-
tor 2 (VEGFR2) antibody ramucirumab in the 
second-line setting.4,5 Thus, there is a clear 
unmet clinical need for better therapies in 
advanced oesophagogastric (OG) cancer. This 
review will focus on some of the immunothera-
peutic approaches being developed, with a major 
emphasis on adenocarcinoma of the stomach and 
oesophagus.
Current position of immunotherapies in OG 
cancers
Across both haematological and solid tumour 
indications, the expansion of the use of immuno-
therapy and specifically immune checkpoint 
inhibitors (ICPIs) is dramatically shifting one of 
the treatment goals in a proportion of patients 
with advanced disease: for some, maintained 
durable responses with elevation in the tail of 
overall survival (OS) curves has become a con-
ceivable treatment goal. The immune landscape 
in OG cancer is, however, thought to differ con-
siderably from other types of cancer, including 
melanoma and non-small cell lung cancer 
(NSCLC), in which ICPI therapies were first 
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licensed. These differences include a mid-to-high 
tumour mutational burden (TMB) range6 and 
variable densities of infiltrating proinflammatory 
T cells.7 Thus, OG cancers may be predicted to 
be less likely to respond to a shift towards the 
enhanced immunogenicity invoked by ICPIs seen 
in tumours with the highest TMB. However, a 
closer look at the biology of immune checkpoint 
molecules may help define a specific role for their 
targeting in OG cancers. The number of identi-
fied immune checkpoint molecules is expanding 
but include cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) and programmed death 1 
(PD-1) and its known ligands PD-L1 and PD-L2.
CTLA-4 is an inhibitory receptor constitutively 
expressed on regulatory T cells and activated 
cytotoxic T cells. It is a CD28 homologue with 
much higher binding affinity for the costimula-
tory immune-activating T-cell receptor, B7.8 
Anti-CTLA-4 antibodies induce an antitumour 
response, probably by inducing an immune prim-
ing phase and reducing regulatory T-cell-
mediated suppression of inflammatory responses.9 
Some of the immune-mediated toxicities 
described for this class of therapeutics are likely 
due to their potential to ablate the role of regula-
tory T cells in maintaining peripheral tolerance.8 
PD-1 is a negative costimulatory receptor 
expressed mainly on activated T cells10 which 
downregulates excessive immune responses by 
binding to its ligands, PD-L1 and PD-L2.11 
PD-L1 is constitutively expressed in various tis-
sues and on an expanding list of several tumour 
types, including OG cancer.12,13 Specifically, 
PD-L1 expression has been detected in more 
than 40% of human gastric cancer samples in sev-
eral studies,12 though its overexpression in 
oesophageal cancer is estimated to be considera-
bly lower at around 15–20%.13 PD-1 blockade is 
postulated to work during the T-cell effector 
phase to restore the immune function of exhausted 
T cells following extended or high levels of anti-
gen exposure, as occurs in advanced cancer.8 
Figure 1 highlights the roles these immune check-
point molecules have on cancer regulation, and 
suggests that their inhibition may have different 
mechanisms of antitumour efficacy.
Two anti-CTLA-4 murine antibodies, ipili-
mumab and tremelimumab, have been assessed 
in OG cancer. A phase II study of tremilumumab 
in the second-line treatment of unselected 
advanced OG cancer showed an overall response 
rate (ORR) of 5% with a mOS of 4.8 months.14 
Of note, and supportive of the proposed mecha-
nism of action of ICPIs, the sole responder con-
tinued treatment beyond 2 years. A phase II study 
assessed the efficacy of ipilimumab as mainte-
nance treatment immediately after first-line 
chemotherapy in locally advanced irresectable or 
metastatic gastroesophageal cancer compared 
Figure 1. CTLA-4 and PD-1 pathway inhibition. CTLA-4 inhibition allows for activation and proliferation of 
more T-cell clones, and reduces Treg-mediated immunosuppression. PD-1 pathway inhibition restores the 
activity of antitumour T cells that have become quiescent.
CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; MHC, major histocompatibility complex; PD-1, programmed death 1; 
PD-L, programmed death ligand 1; TCR, T-cell receptor; Treg, regulatory T cell.
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with best supportive care.15 No difference was 
demonstrated in mOS between the two study 
arms.
After these less than encouraging results, enthu-
siasm for the potential benefits of ICPIs in 
OG cancer was reignited by the preliminary 
results demonstrated in the pembrolizumab, 
KEYNOTE-012 study.16 Pembrolizumab is a 
humanised monoclonal antibody designed to 
bind to PD-1 and thus block the interaction 
between PD-1 and its ligands. In this study, 
patients with PD-L1-positive disease (>1%) were 
enrolled for pembrolizumab as first- or subse-
quent-line therapy (n = 39). An ORR of 22% 
with median duration of responses of 40 weeks 
was observed. The 6-month progression-free sur-
vival (PFS) rate was 26%, and the mOS was 11.4 
months, with a 12-month OS rate of 42%. Of 
note, over 50% of patients had received three or 
more lines of therapy. Pembrolizumab has subse-
quently been licensed by the US Food and Drug 
Administration (FDA) in third-line or more 
advanced PD-L1-positive (>1%) gastric cancer.
Nivolumab is a humanised monoclonal antibody 
to PD-1, which has been evaluated in a number 
of studies in gastric cancer. Most recently, the 
pivotal phase III, placebo-controlled, randomised 
and licensing study was reported for nivolumab in 
third- or subsequent-line therapy. The ONO12 
(ATTRACTION-2) study recruited in Korea, 
Japan and China only, and thus consisted entirely 
of Asian patients.17 Patients were not selected 
according to PD-L1 status. In this large study (n 
= 493), patients were randomised in a 2:1 fash-
ion to nivolumab or placebo. Nivolumab resulted 
in statistically superior OS, PFS and ORR 
(11.2%) compared with placebo. Twelve-month 
OS rates were 26.6% versus 10.9%. Subsequently, 
nivolumab has obtained a license in advanced 
gastric cancer in Japan, while licensing applica-
tions in the US and EU are ongoing. Separately, 
the first study targeting PD-1 in squamous cell 
carcinoma oesophagus with nivolumab was con-
ducted and was unselected for tumour PD-L1 
positivity.18 An ORR of 17% and mOS of 10.8 
months were observed. Of note, for the patients 
who developed investigator-evaluated immune-
related toxicity, ORR was 25%.
Preclinical data have shown that the combination 
of PD-1 and CTLA-4 receptor blockade might 
improve antitumour activity.19 This enhanced 
efficacy may be hypothesised to be due to 
alternative pronged approaches in targeting the 
cancer immunity cycle.20 Indeed, even though the 
single agent CTLA-4 inhibitor studies had failed 
to show an improvement in survival compared 
with placebo, the authors of the ipilimumab phase 
II study argue that its tolerability supports its 
development in combination with other ICPIs.15 
In the CHECKMATE 032 study, both nivolumab 
monotherapy and the combination of nivolumab 
plus ipilimumab were tested in heavily pretreated 
patients with advanced gastric cancer.21 
CHECKMATE 032 allocated patients to 
nivolumab (3 mg/kg) monotherapy and two dose 
schedules of nivolumab plus ipilimumab, 
nivolumab 1 mg/kg and ipilimumab 3 mg/kg, or 
nivolumab 3 mg/kg plus ipilimumab 1 mg/kg. 
The ORR was 14% (nivolumab alone), 26% 
(nivolumab 1, ipilimumab 3), and 10% 
(nivolumab 3, ipilimumab 1). Six-month PFS 
rates were 18%, 24%, and 9%, and 12-month OS 
rates were 39%, 35%, and 24%, respectively. 
There was some correlation between ORR and 
PD-L1 expression (divided into <1%, 1–5%, and 
⩾5%) but no linear relationship. In the nivolumab 
1, ipilimumab 3 subgroup, the PD-L1-positive 
population seemed to derive more of an OS ben-
efit: 12-month OS rate 50% (versus 35%). 
However, due to the increased toxicity observed 
with higher ipilimumab dosing in this trial21 and 
others, many investigators would favour a lower 
ipilimumab dose. A first-line trial combination 
of ICPI (nivolumab + one of four doses of ipili-
mumab) followed by maintenance nivolumab 
versus the investigator’s choice of capecitabine/
oxaliplatin (XELOX) or fluorouracil/leucov-
orin/oxaliplatin (FOLFOX) is recruiting 
[ClinicalTrials.gov identifier: NCT02872116].
After the phase I dose escalation trial of avelumab, 
an anti-PD-L1 antibody in advanced solid 
tumours, showed early evidence of efficacy,22 with 
some isolated reports of meaningful clinical bene-
fit in gastric cancer,23 this drug has been further 
evaluated in the phase Ib expanded cohort 
JAVELIN study in two different settings. During 
second-line treatment, a similar ORR to that 
observed for nivolumab and pembrolizumab 
(15%) was observed. A first-line maintenance 
registration study is ongoing (JAVELIN Gastric 
100) [ClinicalTrials.gov identifier: NCT026-
25610]. Recently, however, a phase III trial com-
paring avelumab with standard of care 
chemotherapy has been reported by the trial spon-
sors not to show a survival improvement.24 Of 
note, recent preliminary data of Keynote-061 in 
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which pembrolizumab was compared to paclitaxel 
in the second-line setting, have also failed to dem-
onstrate an improvement in either PFS or OS.25 
Full results of these studies are yet to be published, 
but in the context of the licensing of nivolumab 
and pembrolizumab in later lines of treatment, 
these data have nonetheless been provocative. It is 
not clear whether biological differences between 
anti-PD-1 and anti-PD-L1 inhibition translate 
into meaningful differences in efficacy between 
these classes of drugs. In a solid tumour phase I 
trial of another anti-PD-L1 antibody, durvalumab, 
activity was observed in gastric cancer, and several 
clinical trials are further investigating this 
compound in this disease.26 PLATFORM is 
one such trial in which, if at least stable disease 
is demonstrated after first-line chemotherapy 
[ClinicalTrials.gov identifier: NCT02678182], 
patients receive one of four maintenance treat-
ments, one of which is durvalumab. This ran-
domised phase II trial has an adaptive study design 
with a plan to expand the effective arms into a 
phase III maintenance trial powered for OS. As 
more robust data become available for other bio-
marker-selected populations (e.g. hepatocyte 
growth factor receptor (MET) positive or 
Fibroblast Growth Factor Receptor (FGFR) 
amplified), it may be possible to amend the overall 
trial design to incorporate these biomarker-tar-
geted maintenance therapies. Table 1 provides a 
summary of the pivotal phase III trials of ICPIs in 
advanced gastric cancer.
Clearly, specific challenges remain in identifying 
biomarkers that may permit better prediction of 
those patients likely to derive benefit from ICPIs 
and, not least due to their high costs, the duration 
of treatment required to maintain responsiveness. 
In this review, we will explore the known and 
hypothesised mechanisms of resistance to and 
predictive biomarkers of response to ICPIs, and 
define strategies which may be used to enhance 
the efficacy and duration of response to these 
agents in advanced OG cancer.
Table 1. Pivotal phase III ICPI studies in OG cancers.




First-line gastric and OGJ
CHECKMATE 649 1266 Nivolumab Capecitabine/5FU/
oxaliplatin
NCT02872116
KEYNOTE 062 750 Pembrolizumab Cisplatin/5FU NCT02494583
First-line maintenance gastric and OGJ
PLATFORM 770 Durvalumab BSC/capecitabine/olaparib NCT02678182
JAVELIN gastric 100 666 Avelumab First-line chemotherapy NCT02625610
Second-line gastric and OGJ
KEYNOTE 061 720 Pembrolizumab Paclitaxel NCT02370498
KEYNOTE 063 (Asia only) 360 Pembrolizumab Paclitaxel NCT03019588
Third-line gastric and OGJ
JAVELIN gastric 300 330 Avelumab Irinotecan/paclitaxel/BSC NCT0262562324
Advanced oesophageal cancer ⩾ two lines
CHECKMATE 473 390 Nivolumab Docetaxel/paclitaxel NCT02569242
KEYNOTE 181 720 Pembrolizumab Docetaxel/paclitaxel/
irinotecan
NCT02564263
5FU, 5-fluoruracil; BSC, best supportive care; ICPI, immune checkpoint inhibitor; N, estimated recruitment; OG, 
oesophagogastric; OGJ, oesophagogastric junction.
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Biomarkers of responsiveness to ICPIs and 
other immuno-oncology (IO) drugs in OG 
cancers
One approach to identifying biomarkers is the fur-
ther molecular refinement of subtypes of gastric 
and oesophageal cancer. The search for new can-
cer genes has exploded through large-scale molec-
ular characterisation initiatives such as The 
Cancer Genome Atlas (TCGA) and the Asian 
Cancer Research Group (ACRG). These types of 
characterisations may more ultimately explain 
why some tumours respond particularly well to 
ICPIs. Interestingly, in gastric cancer, although 
there are similarities between the TCGA and 
ACRG classification systems, only the ACRG 
seems to serve as a useful prognosticator. This 
prognostic difference between the TCGA and 
ACRG may be related to the limited follow up of 
the TCGA, the incorporation of clinical charac-
teristics into the ACRG system and the inclusion 
of molecular aberrations in the ACRG system 
which are not mutually exclusive if applied within 
the TCGA system.27 The TCGA also recently 
reported the genomic characterisation of oesopha-
geal adeno and squamous carcinomas.28 Other 
molecular categorisations of relevance include one 
which attempts to link the alterations to markers 
of potential therapeutic significance.29 The cate-
gories which are defined by this system include 
enrichment for prevalent defects in the homolo-
gous recombination repair pathway, mutational 
patterns associated with a high mutational load 
and those associated with an ageing imprint.
In both oesophageal and gastric cancer, none of 
the defined molecular subtypes on their own have 
been shown to be predictive biomarkers for ICPIs. 
One reason for this may be the fact that most of 
these analyses have been conducted on early, 
resectable cancers, when in fact the situation in 
heavily pretreated advanced cancer is likely to be 
significantly different. Indeed, it seems likely that a 
multifaceted approach will be required in advanced 
disease. In the next sections, isolated biomarkers of 
relevance which may comprise a composite prog-
nostic tool will be explored in some detail.
PD-L1 expression
Across oncology indications, many IO studies 
continue to use PD-L1 expression as a stratifying 
factor. However, the importance of PD-L1 
expression in ICPIs in gastric cancer remains 
unclear. This is for composite reasons, including 
the variable sensitivity of the companion 
diagnostic used to quantify PD-L1 expression 
and the lack of specificity of the cell types on 
which it is being quantified between each of these 
companion diagnostics (Table 2). Most of these 
studies perform PD-L1 quantification by immu-
nohistochemistry on archived tissue, providing 
only a snapshot of PD-L1 intensity and distribu-
tion in one part of the tumour, and may not be 
representative of the changing tumour microenvi-
ronment (TME) in other parts of the primary 
tumour or in subsequent metastases.30 This 
PD-L1 data disparity clearly demonstrates that a 
more complex approach to biomarker identifica-
tion is required.
Mismatch repair deficiency
Microsatellite instability (MSI) occurs as a 
result of defective mismatch repair (MMR).38 
Microsatellites are tiny, repetitive DNA 
sequences which accumulate mutations when 
MMR genes dysfunction or are silenced epige-
netically. MMR deficiency leads to a hypermu-
tated phenotype and high levels of neoantigen 
presentation, and is associated with an enhanced 
response to pembrolizumab across tumour 
types.39 Consequently, the FDA granted pem-
brolizumab accelerated approval for MMR-
deficient solid tumour indications, and was the 
first tumour agnostic approval of its kind in its 
history. In Keynote-012, two of the four patients 
with MMR-deficient gastric cancers demon-
strated a radiological response.16 Indeed, in 
detailed genomic analyses of MMR deficiency 
and its association with other immune factors, 
both MMR deficiency and tumour-infiltrating 
lymphocyte (TIL) presence were associated with 
better prognosis. Keynote-059 cohort 3 data in 
which patients with PD-L1 positive tumours 
(combined proportion score of ⩾1%) were 
enrolled to receive pembrolizumab in the first 
line was recently published.33 Similarly, in this 
study, ORR values were dramatically better in 
patients whose tumours demonstrated high MSI 
compared with those patients whose tumours did 
not (57.1% versus 9%). It could be hypothesised 
that patients with these features may be more 
likely to respond to PD-1 targeting.40
Tumour mutational burden
The utility of TMB as a prognostic biomarker is 
becoming increasingly evident across tumour 
types. The first detailed study examining whether 
a correlation between mutational burden and 
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response to CTLA-4 blockade could be demon-
strated was conducted in patients with melanoma.41 
Indeed those patients with a higher TMB had 
better responses to CTLA-4 inhibition and this 
provided a rationale for examining exomes of 
patients for whom anti-CTLA-4 agents was 
being considered. Similarly, higher TMB has 
been shown to predict a favourable outcome to 
PD-1/PD-L1 blockade across diverse tumours.42 
In addition, in the recently published anti-PD-1/
CTLA-4 combination first-line study in NSCLC, 
PFS among patients with a high TMB was sig-
nificantly longer with nivolumab plus ipilimumab 
than with chemotherapy.43
Mechanistically, a high density of neoepitopes 
stemming from either somatic driver or passenger 
mutations may permit more ready immune detec-
tion after ICPIs, leading to destruction of cells 
bearing these mutation-associated neoantigens.44 
Routine analysis of neoantigens was not realistic 
until the recent evolution in high-throughput 
next-generation sequencing technology. The 
feasibility of using a targeted sequence panel as a 
surrogate for the whole-exome TMB has been 
tested6 and is likely to become increasingly uti-
lised. However, problems in the definition of 
thresholds of higher TMBs and whether TMB is 
expressed as total number of mutations/exome, or 
mutations per megabase differ between studies 
and make interstudy interpretation of its utility as 
a predictive biomarker difficult to ascertain. Apart 
from the definition of the number of mutations, 
subtypes of mutations may be relevant, including 
whether they represent frameshift insertion/dele-
tion versus nonsynonymous single nucleotide var-
iants.45 Tumour mutational analyses are 
nevertheless becoming significantly refined46 and 
are likely to permit more tailored treatment selec-
tion in future years.













22C3 (DAKO) NSCLC first line TPS ⩾ 50% Reck et al.31
NSCLC ⩾ second line TPS ⩾ 1% Herbst et al.32
Metastatic OGJ/
gastric cancer  
> second line
CPS ⩾ 1% Fuchs et al.33
Companion diagnostic not required in license but benefit shown in stated subpopulations
Nivolumab PD-1 
inhibitor
28-8 (DAKO) NSCLC ⩾ second line TC ⩾ 1% Borghaei et al.34
Atezolizumab PD-L1 
inhibitor
SP142 (Ventana) NSCLC ⩾ second line TC or TI ICs ⩾ 1% Rittmeyer et al.35
Urothelial cancer  
⩾ second line or first 
line in those patients 
unfit for cisplatin
⩾ 5% TI ICs Powles et al.36
Durvalumab PD-L1 
inhibitor
SP263 (Ventana) Urothelial cancer  
⩾ second line or first 
line in those patients 
unfit for cisplatin
IC > 1%:
TC or IC ⩾ 25%
or
IC ⩽ 1%:
TC ⩾ 25% or IC = 100%
Powles et al.37
CPS = number of PD-L1 staining cells (tumour cells, lymphocytes, macrophages)/total cells × 100.
IC, immune cell; FDA, US Food and Drug Administration; NSCLC, non-small cell lung cancer; OGJ, oesophagogastric junction; PD-L1, 
programmed death ligand 1; TC, tumour cell; TI IC, tumour-infiltrating immune cell; TPS, tumour proportion score; CPS, combined proportion 
score.
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Immune cell gene expression signatures
It has previously been shown that gastric cancer 
in Asian and non-Asian patients might exhibit 
distinct gene signatures related to inflammation 
and immunity.47 In particular, immune T-cell 
expression signatures were enriched in non-
Asian gastric cancers, including both CD28 and 
CTLA-4 signalling, with supportive immunohis-
tochemistry data showing T-cell markers (CD3, 
CD45R0, and CD8) significantly enriched in 
gastric cancer in white patients compared with 
Asian patients. The exception was the immuno-
suppressive T-regulatory cell marker FOXP3, 
which was significantly enriched in the Asian 
population. Additionally, notable increased 
expression of the macrophage marker CD68 
occurred in non-Asian patients. In multivariate 
analysis, only CD68 and CD3 expressions were 
independently associated with survival, and a 
high CD68/CD3 ratio was predictive of worse 
OS. These have not yet been investigated as pre-
dictive biomarkers. These immune-related dif-
ferences were distinct and unrelated to 
Epstein-Barr virus (EBV) infection and MMR 
status. Interferon (IFN)-γ gene set enrichment 
was however more frequently seen in EBV-
infected and MSI subgroups, although there was 
no association between IFN-γ signature and 
total number of mutations.48 Although T-cell 
expression signatures are becoming easier to 
measure,49,50 their reliability as predictive bio-
markers needs to be verified. Indeed, in the 
Keynote-012 study, the identified IFN-γ gene 
expression signature did not significantly predict 
response to pembrolizumab,16 although larger-
scale analyses may yet prove its value as a predic-
tive tool. For example, the 18-gene 
T-cell-inflamed gene expression profiling score 
utilized in the Keynote-059 study did indeed 
demonstrate a higher score in aggregate for 
responders than for nonresponders.33
Other potential biomarkers of interest
Helicobacter pylori. Apart from its well estab-
lished aetiological role in gastric cancer, Helico-
bacter pylori inflammation occurring secondary to 
H. pylori infection alters the gastric microenviron-
ment in multiple ways. H. pylori infection increases 
the levels of DNA methylation of tumour sup-
pressor genes, and the induction of inflammation-
related genes,51 which may be responsible for 
inducing a T-cell response in gastric mucosa and 
increasing expression of PD-L1. It might there-
fore be hypothesised that H. pylori-driven tumours 
might be more likely to respond to ICPIs, although 
there is no randomised clinical evidence for this.
Epstein-Barr virus
Amplification of the 9p24.1 locus, which leads to 
PD-L1 overexpression, is observed in approxi-
mately 11–15% of EBV-positive gastric cancer 
cases.52,53 However, other mechanisms responsi-
ble for PD-L1 upregulation aside from PD-L1 
gene amplification in EBV-positive gastric cancer 
might include IFN-γ induction of PD-L1 expres-
sion via activation of JAK2/STAT1/IRF-1 signal-
ling in cancer cells.54 EBV-infected cancer such as 
Hodgkin’s lymphoma may respond well to 
ICPIs.55 However, limited clinical data are avail-
able on the interaction between EBV status and 
ICPIs in gastric cancer.
T-cell receptor repertoire and gut microbiome
The role of T-cell receptor clonality and diversity 
in predicting response to ICPIs is the subject of 
investigations in many laboratories.56 The associ-
ations between microbiome diversity and nonre-
sponse to ICPIs have also been recently 
described.57,58 It is becoming apparent that pri-
mary resistance to ICPIs can be due to specific 
gut microbiome profiles and that antibiotics 
which alter this profile may limit the clinical effi-
cacy of ICPIs. In keeping with this, faecal trans-
plantation from ICPI-responding patients into 
germ-free or antibiotic-treated mice improved 
ICPI antitumour efficacy.58 The mechanisms by 
which specific enteric bacteria modify the immune 
response during immunotherapy remain largely 
obscure, although the cross reactivity between 
microbial and tumour antigens is thought to 
enhance immune cell priming.59
Mechanisms of acquired resistance to ICPIs
Many patients who have had an initial objective 
response to ICPIs will go on to relapse despite 
continuous immunotherapy treatment.60 Factors 
which predispose patients to acquired ICPI resist-
ance may include the acquisition of defective 
mechanisms for tumour antigen presentation, 
which predominantly occurs via alterations in 
major histocompatibility complex (MHC) class I 
expression, genetic or epigenetic alterations 
within immunogenic signalling pathways, and a 
shift towards an immunosuppressed tumour 
microenvironment.61 There is clearly a role for 
treatments which may target each of these 
Therapeutic Advances in Medical Oncology 10
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acquired resistance mechanisms and enhance the 
likely benefit which could be derived from ICPIs.
The loss of β2-microglobulin (B2M) is an exam-
ple of an established mechanism of acquired 
resistance to immunotherapy which results from 
defective antigen presentation.62,63 B2M loss is 
thought to specifically interfere with MHC class I 
heavy chain folding, leading to a loss of its recep-
tor localisation and curtailment of downstream 
signalling. Another mechanism for resistance 
development may be altered oncogenic signalling 
of tumour cells, with the IFN signalling pathway 
being the most intensively studied.64 During ICPI 
treatment, multiple inhibitory checkpoints might 
also be upregulated because of IFN signalling65 
and activation of various pathways66 in tumour-
infiltrating lymphocytes (TILs), ultimately lead-
ing to therapeutic failure. For example, T-cell 
immunoglobulin and mucin-domain containing 3 
(TIM-3), an immune checkpoint, has been 
upregulated in lesions from patients with lung 
adenocarcinoma who initially had a partial 
response to anti-PD-1 therapy.67 Alterations in 
the WNTβ-catenin signalling pathway,68 signal-
ling alterations resulting from either phosphatase 
and tensin homolog (PTEN) loss or phosphati-
dylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PI3KCA) mutations in tumour 
cells69 and other receptor tyrosine kinases includ-
ing epidermal growth factor receptor,70 may all 
contribute to an immunosuppressive phenotype. 
Resistance to ICPIs may also occur via alterations 
in the tumour immune milieu. Greater infiltration 
of immunosuppressive myeloid cells, including 
type 2 tumour-associated macrophages, has been 
shown to correlate with ICPI resistance.71 
Chemokines play an important role in optimal 
T-cell recruitment to tumours following activa-
tion of the stimulator of IFN genes (STING) 
pathway in dendritic cells (DCs)72,73 and curtail-
ment in type 1 IFN activity will likely result in 
reduced inflammatory T-cell infiltration. 
Alterations in the activity of other chemokines, 
including CXCR4, may contribute to this immu-
nosuppressive phenotype. Alternatively, meta-
bolic processes within the TME have also been 
shown to reduce immunogenicity, including 
altered adenosine metabolism which pivots the 
immune milieu towards one favouring immune 
suppression.74 Alterations in angiogenesis may 
also play a role in the development of ICPI resist-
ance.75 Figure 2 provides an overview of some of 
the changes that may occur in the TME during 
tumour progression, each of which contributes 
towards an immunosuppressive environment, 
T-cell anergy, and immune escape.
Role of combination of ICPI with 
chemotherapy, targeted therapies, 
radiotherapy and other immuno-oncology 
drugs
The success of ICPI treatment across solid 
tumours has initiated a flurry of research into 
optimal combination strategies. Some of the rea-
sons for primary and acquired resistance against 
ICPIs have been outlined and perhaps provided a 
justification for how combination therapies may 
be used to circumvent these. The optimal treat-
ment of OG cancers has very specific considera-
tions of the most appropriate combination 
therapies which will be outlined in this section.
Immuno-oncology and chemotherapy or 
radiotherapy
The rationale for the enhancement of the anti-
tumour effects of chemotherapies by their 
upregulation of immunogenicity is not novel. 
Some chemotherapeutics are thought to be par-
ticularly immunogenic,76 inducing immunogenic 
cell death by the combination of exposure of dan-
ger-associated molecular patterns, their recogni-
tion by toll-like receptors, and subsequent DC 
activation.74 Of relevance to gastric cancer, a 
30-year-old trial which combined Vibrio cholerae 
neuraminidase (VCN) treated autologous tumour 
cells and bacillus calmette-guerin (BCG) with 
cyclophosphamide, mitomycin C and 5-fluoro-
uracil, showed improved survival relative to 
historical controls,77 suggesting a recognised 
potential benefit of harnessing the immune sys-
tem to improve chemotherapy responsiveness in 
this disease. Of relevance in ICPI-resistant mod-
els, pretreatment with chemotherapy may in fact 
induce ICPI sensitivity. This is demonstrated in a 
mouse model of NSCLC, in which oxaliplatin 
plus cyclophosphamide pretreatment rendered 
anti-CTLA-4 and anti-PD-1 antibodies effica-
cious.78 Although data in gastric cancer models 
are lacking, these NSCLC model data do support 
a role for oxaliplatin-enhanced immunogenicity. 
In addition, preclinical data in BRCA1-deficient 
triple-negative breast cancer models suggest that 
cisplatin may be utilised to increase mutational 
burden and enhance responsiveness to combina-
tion immunotherapy.79 As a proportion of patients 
with gastric cancer harbour defects in homologous 
recombination repair,80 an understanding of how 
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platinum drugs may be utilised to enhance immu-
notherapy efficacy should continue to be sought.
Clinical efficacy data of combinations of immu-
notherapy with chemotherapy in OG cancer are 
evolving and perhaps the most relevant presented 
data in the advanced setting were demonstrated 
in the other cohorts of Keynote-059, in which 
pembrolizumab was given either with or without 
chemotherapy.81 Cohort 1 patients received pem-
brolizumab alone after at least two prior lines of 
therapy. Cohort 2 patients received pembroli-
zumab and cisplatin and 5-fluorouracil or capecit-
abine in the first-line setting. Confirmed ORR 
was 12% in cohort 1 and 60% in cohort 2. Median 
PFS was two and seven in cohorts 1 and 2, respec-
tively. Further large randomised trials comparing 
and combining immuno-oncology (IO) with 
chemotherapy are ongoing (Table 1).
Similarly to the immunogenicity that chemo-
therapy is thought to enhance, radiotherapy has 
been shown to be associated with upregulation 
of PD-L1 in the tumour microenvironment 
(Teng et al. 2014).82 Indeed, the coadministra-
tion of ICPIs with radiotherapy seems to trans-
late to an enhanced efficacy of radiotherapy 
given alone. There is thus at least one currently 
recruiting clinical study combining ICPI with 
radiotherapy in advanced OG cancer 
[ClinicalTrials.gov identifier: NCT02830594].
IO and targeted therapies
Targeted therapies have provided a basis for the 
revolution of personalised cancer medicine over 
the last 25 years. However, most patients will 
develop resistance to these agents as resistant 
clones develop strategies to overcome inhibition 
of the targeted driver mutation. In OG cancer, 
few targeted agents have shown superior evidence 
of efficacy over standard of care approaches. 
Antiangiogenics. The VEGFR2 antibody ramuci-
rumab is now an established therapeutic option in 
the second-line treatment of advanced gastric 
cancer, either as a single agent or in combination 
with paclitaxel.4,5 There is evidence that VEGFR2 
Figure 2. The shift towards an immunosuppressed tumour microenvironment (TME) during tumour 
progression. Tumour cells stimulate the recruitment of myeloid and lymphoid derived immune cells, including 
macrophages, CD4+ Tregs, and MDSCs, to the TME via secretion of key cytokines that are chemotactic 
for these cell types. Tumour-cell derived anti-inflammatory cytokines, TGF-β1, and macrophage colony-
stimulating factor (M-CSF) induce macrophages, CD4+ T cells, and MDSCs to upregulate immune-suppressive 
molecules including IL-10, TGF-β1, and CTLA-4, as well as pro-angiogenic factors. This results in further 
immune suppression, altered metabolism, and angiogenesis in the TME, promoting tumour progression. 
CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; IDO, indoleamine-2,3 dioxygenase; IL, interleukin; TGF, 
transforming growth factor; Treg, regulatory T cell; MDSC, myeloid-derived suppressor cells.
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pathway activation by VEGFA might suppress 
antitumour T-cell activation, including via block-
ing the maturation of and upregulation of PD-L1 
on DCs and enhancing regulatory T-cell activity.83 
Preclinical data have demonstrated that low doses 
of the murine parent antibody to ramucirumab, 
DC101, reprogrammes the TME and potentiates 
the antitumour efficacy of ICPIs.84 In a colon 
adenocarcinoma murine model, a synergistic 
inhibitory effect of DC101 with anti-PD-1 ther-
apy was demonstrated.85 Crucially, vascular nor-
malisation with antiangiogenic targeted therapies 
has been shown to reverse immunotherapy resis-
tance in patients.86 To test the safety and early 
efficacy of the combination of an antiangiogenic 
agent with ICPI in gastric cancer specifically, a 
phase I study combining pembrolizumab and 
ramucirumab in PD-L1-unselected multitumour 
patient cohorts has been initiated [ClinicalTrials.
gov identifier: NCT02443324]. The safety profile 
was favourable, allowing administration of each 
drug at full dose.87 Some early efficacy data have 
demonstrated antitumor activity (7.5% ORR) in 
previously treated gastric adenocarcinoma.
Targeting the angiogenic pathway with vaccine 
therapy is also an approach associated with some 
activity in gastric cancer. A vaccine against HLA-
A24-restricted human VEGFR1-1084 and 
VEGFR2-169 demonstrated that for those 
patients who had an immunological response to 
the VEGFR2-169 peptides, there was a statisti-
cally significantly improved OS.88
An alternative target of angiogenesis is the 
matrix metalloproteinase family of proteins. 
Andecaliximab binds to MMP-9 and inhibits its 
enzymatic activity, resulting in the inhibition of 
extracellular matrix protein degradation.89 
Although there was preliminary evidence of effi-
cacy in ulcerative colitis,88 the phase III trial of this 
agent was terminated early due to perceived futil-
ity. However, what can be gleaned from the 
knowledge of the basal activity of this enzyme is 
the predicted inhibition of angiogenesis, tumour 
growth, and metastasis. Thus, a phase II clinical 
trial combining andecaliximab with nivolumab in 
oesophagogastric junction (OGJ/gastric adenocar-
cinoma has completed recruitment [ClinicalTrials.
gov identifier: NCT02864381] and the results are 
pending. By a similar mechanism, the mesothelin 
inhibitor CRS-207 is being trialled in patients 
with advanced or metastatic OGJ/gastric adeno-
carcinoma in combination with pembrolizumab 
[ClinicalTrials.gov identifier: NCT03122548].
Poly ADP (adenosine diphosphate)-ribose poly-
merase (PARP) inhibition. A large-scale study of 
10,250 cancer genomes across cancer types dem-
onstrated that, in addition to breast, ovarian and 
pancreatic cancers, gastric cancer exhibits defects 
in DNA repair.80 Specifically, 7–12% of gastric 
cancers in this analysis had defective double-strand 
DNA break repair. Other markers of correct to 
homologous recombination repair (HRR) defi-
ciency may include loss-of-function ataxia-telangi-
ectasia mutated (ATM) tumours, which are 
thought to occur in 16–22% of patients with gas-
tric cancer.90 Although a phase II combination trial 
of the PARP inhibitor (PARP-i) olaparib and pacli-
taxel had shown early signs of promising activity, 
especially in ATM-deficient tumours,91 a ran-
domised phase III trial of olaparib plus paclitaxel 
versus placebo plus paclitaxel followed by olaparib 
or placebo (GOLD) failed to show a significant 
survival benefit.92 Ongoing genetic analyses of 
GOLD will likely yield reasons for this apparent 
discrepancy. In view of the fact that tumours with 
HRR deficiencies may be particularly sensitive to 
immunotherapeutics given the potentially high 
mutagenic burden in tumours with BRCAness,93 it 
may be worth continuing to explore this avenue in 
gastric cancer. For example, BRCA1-deficient tri-
ple-negative breast cancer is known to be associ-
ated with a high TMB and high CTL infiltration.79 
The PARP-i talazoparib has been shown to increase 
the percentage of cytotoxic CD8+ T cells, B cells, 
and natural killer cells on a BRCA1-deficient ovar-
ian tumour cell line grown in the peritoneal cavity 
of tumour-bearing mice.94 These observations sug-
gest that ICPIs in combination with PARP-i may 
have potential therapeutic benefit and an in vivo 
BRCA1-deficient ovarian cancer model estab-
lished in an immune-competent host was used to 
show that an anti-CTLA-4 antibody synergised 
with the PARP-i veliparib, resulting in an OS ben-
efit for these animals.95 Consequently, at least one 
trial is investigating the PARP-i/immunotherapy 
combination in advanced solid tumours [Clinical-
Trials.gov identifier: NCT02734004].
HER2 inhibition. The rationale for the combina-
tion of anti-HER2 antibodies with immunothera-
pies in HER-2-positive gastric cancer96 is based 
on trastuzumab’s well established efficiency in 
inducing antitumour activity via mediating anti-
body-dependent cell-mediated cytotoxicity,97 
increasing tumour lymphoid infiltration and 
reducing T-regulatory cell activity.98 Combining 
this ability to enhance adaptive immunity with 
ICPIs has been shown to demonstrate synergism 
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in vivo.99 The PANACEA trial [ClinicalTrials.gov 
identifier: NCT02129556] is evaluating the effi-
cacy of pembrolizumab and trastuzumab in 
patients with trastuzumab-resistant, HER2-posi-
tive metastatic breast cancer (MBC). The trastu-
zumab emtansine antibody drug conjugate 
T-DM1 is also being evaluated in combination 
with atezolizumab in patients with HER2-positive 
MBC whose disease has progressed on trastu-
zumab and a taxane [ClinicalTrials.gov identifier: 
NCT02924883]. Another ongoing phase Ib/II 
clinical trial is investigating the clinical activity 
and safety of the combination of pembrolizumab 
with trastuzumab, capecitabine, and cisplatin 
[ClinicalTrials.gov identifier: NCT02901301].
IO/IO drug combinations
In the setting of metastatic melanoma and recur-
rence after prior anti-PD-1 therapy irrespective of 
prior response to PD-1 inhibition, an alternative 
ICPI approach, CTLA-4 inhibition, demon-
strated efficacy in some patients.100 This study 
highlights the potential benefit of alternative 
approaches in the unmasking of the immune sys-
tem’s antitumour efficacy. In this section, we dis-
cuss the rationale for and evolution of newer 
strategies of combining immune system targeted 
therapies in oesophagogastric cancer.
Combinations of ICPI with other ICPI or T-cell ago-
nists. There are a number of adaptive-designed, 
phase II studies either recruiting or being planned to 
combine different IO agents in all solid tumours, 
including gastric cancer. For example, FRAC-
TION-GC (a phase II, Fast Real-time Assessment 
of Combination Therapies in Immuno-Oncology 
study in patients with advanced gastric cancer) is 
currently randomising patients between nivolumab 
plus ipilumumab versus nivolumab plus the anti-
LAG3 (lymphocyte activation gene 3) antibody 
BMS-986016, with scope to add further 
IO compounds [ClinicalTrials.gov identifier: 
NCT02935634]. An alternative approach being 
tested in advanced solid tumours including gastric 
cancer combines the anti-PD-L1 antibody ave-
lumab with a selection of T-cell agonists, utomi-
lumab (4-1BB agonist monoclonal antibody 
(mAb)), PF-04518600 (OX40 agonist mAb), the 
combination of the latter two or PD 0360324 (mac-
rophage colony-stimulating factor (M-CSF) mAb) 
[ClinicalTrials.gov identifier: NCT02554812].
Targeting the TME. Tumour development is associ-
ated with the generation of an immunosuppressive 
tumour milieu consisting of multiple cell types, 
extracellular matrix, and metabolic mediators.101 
Each of these components potentially represents a 
hurdle to CTLs and their antitumour immune 
responses. One example of a TME metabolic medi-
ator showing promise is the potent indoleamine-2,3 
dioxygenase (IDO) inhibitor epacadostat. The IDO 
family of heme-dioxygenases catalyses the conver-
sion of tryptophan to kynurenine and other 
metabolites that drive maintenance of an immuno-
suppressive TME in many cancers.102 IDO inhibi-
tion synergises with ICPIs in preclinical models in 
their activation of intratumoural CD8+ T cells.68 
Based on the provisional positive results of trials 
combining nivolumab with the IDO inhibitor 
epacadostat103 and pembrolizumab,104 a further 
phase I/II study is currently assessing the safety and 
preliminary efficacy of epacadostat in combination 
with durvalumab in subjects with selected advanced 
solid tumours, including gastric cancer [Clinical-
Trials.gov identifier: NCT02318277]. Preclinically, 
A2AR inhibition synergises with ICPIs105 and 
recruiting early phase trials in advanced solid 
tumours include the combination of durvalumab 
with the A2AR antagonist AZD4635 [ClinicalTri-
als.gov identifier: NCT02740985].
Adoptive transfer therapies. Amplification of 
patient derived T cells ex vivo followed by reinfu-
sion has been successful in melanoma; although 
few studies have been conducted in patients with 
gastric cancer.106 A 44-patient study assessed the 
efficacy of adoptive immunotherapy with patient-
derived tumour associated lymphocyte lines 
either in conjunction with chemotherapy or with 
chemotherapy alone.107 Median survival was 8.5 
months for the control chemotherapy alone 
group and 11.4 months for patients treated with 
adoptive T-cell therapy plus chemotherapy, 
though this result was not statistically significant. 
Chimeric antigen receptors (CARs) are engi-
neered antigen receptor proteins consisting of an 
antigen-binding region and T-cell receptor sig-
nalling domains.108 With this technology, T cells 
are genetically modified to express CARs, 
expanded ex vivo and adoptively transferred to 
patients, acting to redirect T cells’ effector func-
tions upon binding to antigens on tumour cells. 
They are quicker to produce, are not restricted 
by human leukocyte antigen (HLA) type, and 
react to a wider range of molecules, thus making 
them more practical than TIL transfer. Although 
most often mentioned in the context of haemato-
logical malignancies, CAR T-cell technologies are 
becoming more refined and are likely to play an 
Therapeutic Advances in Medical Oncology 10
12 journals.sagepub.com/home/tam
increasingly significant role in the treatment of 
solid tumours. For example, a phase I study using 
CEA-targeted CAR T cells in carcino-embryonic 
antigen (CEA)-positive gastric cancer and other 
solid tumours is ongoing [ClinicalTrials.gov 
identifier: NCT02349724].
Vaccine therapies, gut microbiota and oncolytic 
viruses. T cells may also be honed to tumour cells 
by vaccination. The general purpose of a cancer 
vaccine is to expand or boost a patient’s tumour 
antigen-specific T cells.108 Vaccine therapies seek to 
exploit cellular immune responses to cancer anti-
gens. Such antigens may be delivered to the host 
immune system as peptides or via DCs, which 
when activated act as powerful immune activators, 
though this is rapidly ablated by CD8+ lympho-
cytes. Use of NY-ESO-1 peptide (which is expressed 
in gastrointestinal cancers including oesophageal 
cancer) vaccines led to T-cell responses and tumour 
regression in at least one study.109 DCs pulsed with 
tumour cell antigens have produced some initial 
promising results in gastric cancer. In one early 
study, a gastrointestinal tumour overexpressed 
MAGE-A3 peptide pulsed DCs were able to induce 
specific T-cell responses and minor tumour regres-
sion in some patients.110 However, to enhance the 
short-lived immune responses seen in these small 
case series, multiple peptide personalised cancer 
vaccines are being developed and tested in combi-
nation with adjunctive approaches.111
A better understanding of gut microbiota diver-
sity will permit the selection of approaches that 
will facilitate the development of adjunctive ther-
apies, including appropriate antibiotic, probiotic 
formulations, or commensal antigens with molec-
ular mimicry to tumour antigens.61 In a similar 
vein to the immune responsiveness induced by 
peptide vaccination, oncolytic viruses are thought 
to enhance immunogenicity. Newcastle disease 
viruses (NDV)-D90 induce gastric cancer cell 
apoptosis by stimulation of p38 signalling, sup-
pression of ERK1/2 and Akt signalling, and angi-
ogenesis inhibition.112 In vivo, orthotopic injection 
of NDV-D90 impaired tumour growth and 
induced intratumoural necrosis, and clinical trials 
of other oncolytic viruses including recombinant 
vesicular stomatitis virus are underway 
[ClinicalTrials.gov identifier: NCT02923466].
Conclusion and perspective
Survival increments in advanced OG cancers 
have plateaued in the last decade, underlining the 
unmet clinical need for innovations in treating 
this group of diseases. In the current era of dem-
onstrated ICPI successes across solid tumour 
malignancies, trials of ICPIs in OG cancers have 
expanded and have thus far met with variable suc-
cess. These cancers have traditionally been con-
sidered to be more challenging to treat with 
immunotherapy than some other malignancies 
because of their variable mutational burden and 
infiltrating proinflammatory T cells. However, 
the OG cancers of responding patients demon-
strate particular immune and molecular charac-
teristics that make them particularly susceptible 
to ICPIs, with new predictive biomarkers of 
responsiveness continuing to be discovered and 
refined. Indeed, development of an understand-
ing of acquired resistance mechanisms to ICPIs 
by a shift towards translational approaches to 
genomic profiling will encourage recruitment of 
patients into biomarker-driven combination tri-
als. In order to bypass primary resistance mecha-
nisms and to curb the development of resistance 
to ICPIs, an explosion in the numbers of rational 
combination strategies has taken place. Dynamic 
collaboration between industry, academic scien-
tists and clinicians will be needed to accelerate 
those combination strategies most likely to be 
transformative for our patients.
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